MedTrace Logo

Thalassemia Treatment Based on the Stem Cell Technology

NCT03222453 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2017-07-19

No results posted yet for this study

Summary

In order to study the transplantation effect of hematopoetic stem cells from beta-thalassemia induced pluripotent stem cells. We applied clinical grade source of autologous hematopoietic stem cell for the treatment of beta-thalassemia patients, detecting the homing of hematopoietic stem cell transplantation, the differentiation of hematopoietic stem cells in vivo and the hemoglobin beta-chain (HBB) protein expression in the body of recovery, etc., as well as to make a research on the efficacy and safety of hematopoietic stem cells from beta-thalassemia induced pluripotent stem cells.

Conditions

Interventions

BIOLOGICAL

Hematopoetic stem cells

Patient will inject with hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences

    collaborator UNKNOWN

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Xiaofang Sun

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-01
Primary Completion
2016-06-14
Completion
2017-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03222453 on ClinicalTrials.gov